137 related articles for article (PubMed ID: 12635655)
1. Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions.
Ishiwata Y; Okamoto M; Yokochi S; Hashimoto H; Nakamura T; Miyachi A; Naito Y; Yoshikawa T
J Pharm Pharmacol; 2003 Feb; 55(2):229-37. PubMed ID: 12635655
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
[TBL] [Abstract][Full Text] [Related]
3. The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism.
Melarange R; Spangler R; Hoult JR
Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):195-200. PubMed ID: 8931119
[TBL] [Abstract][Full Text] [Related]
4. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Dig Dis Sci; 1992 Dec; 37(12):1847-52. PubMed ID: 1473433
[TBL] [Abstract][Full Text] [Related]
5. Low direct cytotoxicity of nabumetone on gastric mucosal cells.
Arai Y; Tanaka K; Ushijima H; Tomisato W; Tsutsumi S; Aburaya M; Hoshino T; Yokomizo K; Suzuki K; Katsu T; Tsuchiya T; Mizushima T
Dig Dis Sci; 2005 Sep; 50(9):1641-6. PubMed ID: 16133963
[TBL] [Abstract][Full Text] [Related]
6. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.
Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
Br J Rheumatol; 1990 Apr; 29(2):116-9. PubMed ID: 2108782
[TBL] [Abstract][Full Text] [Related]
7. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
Soma LR; Uboh CE; Rudy JA; Smith MS
Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
[TBL] [Abstract][Full Text] [Related]
8. The unique pharmacologic profile of nabumetone.
Blower PR
J Rheumatol Suppl; 1992 Nov; 36():13-9. PubMed ID: 1474529
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
Dandona P; Jeremy JY
Drugs; 1990; 40 Suppl 5():16-24. PubMed ID: 2081487
[TBL] [Abstract][Full Text] [Related]
10. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function.
Melarange R; Rashbrook LC
J Pharm Pharmacol; 1987 Sep; 39(9):717-20. PubMed ID: 2445949
[TBL] [Abstract][Full Text] [Related]
12. Analysis of pathogenic elements involved in gastric lesions induced by non-steroidal anti-inflammatory drugs in rats.
Takeuchi K; Kato S; Nishiwaki H; Hirata T
J Gastroenterol Hepatol; 1997 May; 12(5):360-7. PubMed ID: 9195381
[TBL] [Abstract][Full Text] [Related]
13. Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats.
Tibble J; Sigthorsson G; Caldwell C; Palmer RH; Bjarnason I
Aliment Pharmacol Ther; 2001 Dec; 15(12):2001-8. PubMed ID: 11736732
[TBL] [Abstract][Full Text] [Related]
14. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation.
Kirchner T; Aparicio B; Argentieri DC; Lau CY; Ritchie DM
Prostaglandins Leukot Essent Fatty Acids; 1997 Jun; 56(6):417-23. PubMed ID: 9223651
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of taurine on indomethacin-induced gastric mucosal injury.
Son M; Kim HK; Kim WB; Yang J; Kim BK
Adv Exp Med Biol; 1996; 403():147-55. PubMed ID: 8915352
[TBL] [Abstract][Full Text] [Related]
16. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
Friedel HA; Langtry HD; Buckley MM
Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indometacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal disease.
Rainsford KD; Stetsko PI; Sirko SP; Debski S
J Pharm Pharmacol; 2003 May; 55(5):661-8. PubMed ID: 12831509
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy.
Wallace JL; Keenan CM; Cucala M; Mugridge KG; Parente L
Gastroenterology; 1992 Apr; 102(4 Pt 1):1176-85. PubMed ID: 1348040
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of nabumetone, naproxen, piroxicam, and diclofenac on rat gastric irritancy following acute exposure to OTC non-steroidal anti-inflammatory agents and other gastric irritants.
Carryl OR; Spangler RS
Scand J Rheumatol; 1995; 24(6):336-41. PubMed ID: 8610216
[TBL] [Abstract][Full Text] [Related]
20. Polymorphonuclear leukocytes activation: in vitro modulation by 6-methoxy-2-naphthylacetic acid, the major active metabolite of nabumetone.
Allegrezza-Giulietti A; Serretti R; Peroni M; Cervini C
Pharmacol Res; 1993 Sep; 28(2):163-73. PubMed ID: 8278307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
